Literature DB >> 16436388

Regulation of fibroblast growth factor-23 signaling by klotho.

Hiroshi Kurosu1, Yasushi Ogawa, Masayoshi Miyoshi, Masaya Yamamoto, Animesh Nandi, Kevin P Rosenblatt, Michel G Baum, Susan Schiavi, Ming-Chang Hu, Orson W Moe, Makoto Kuro-o.   

Abstract

The aging suppressor gene Klotho encodes a single-pass transmembrane protein. Klotho-deficient mice exhibit a variety of aging-like phenotypes, many of which are similar to those observed in fibroblast growth factor-23 (FGF23)-deficient mice. To test the possibility that Klotho and FGF23 may function in a common signal transduction pathway(s), we investigated whether Klotho is involved in FGF signaling. Here we show that Klotho protein directly binds to multiple FGF receptors (FGFRs). The Klotho-FGFR complex binds to FGF23 with higher affinity than FGFR or Klotho alone. In addition, Klotho significantly enhanced the ability of FGF23 to induce phosphorylation of FGF receptor substrate and ERK in various types of cells. Thus, Klotho functions as a cofactor essential for activation of FGF signaling by FGF23.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436388      PMCID: PMC2637204          DOI: 10.1074/jbc.C500457200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway.

Authors:  Tetsuo Yamashita; Morichika Konishi; Ayumi Miyake; Ken-ichi Inui; Nobuyuki Itoh
Journal:  J Biol Chem       Date:  2002-05-24       Impact factor: 5.157

2.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.

Authors:  Yuji Yamazaki; Ryo Okazaki; Minako Shibata; Yukihiro Hasegawa; Kohei Satoh; Toshihiro Tajima; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Takeyoshi Yamashita; Seiji Fukumoto
Journal:  J Clin Endocrinol Metab       Date:  2002-11       Impact factor: 5.958

3.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.

Authors:  Kenneth B Jonsson; Richard Zahradnik; Tobias Larsson; Kenneth E White; Toshitsugu Sugimoto; Yasuo Imanishi; Takehisa Yamamoto; Geeta Hampson; Hiroyuki Koshiyama; Osten Ljunggren; Koichi Oba; In Myung Yang; Akimitsu Miyauchi; Michael J Econs; Jeffrey Lavigne; Harald Jüppner
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

4.  Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho.

Authors:  Shinji Ito; Toshihiko Fujimori; Akiko Furuya; Junko Satoh; Yoko Nabeshima; Yo-Ichi Nabeshima
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

5.  Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.

Authors:  Takashi Shimada; Takanori Muto; Itaru Urakawa; Takashi Yoneya; Yuji Yamazaki; Katsuya Okawa; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Endocrinology       Date:  2002-08       Impact factor: 4.736

6.  Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane.

Authors:  Akihiro Imura; Akiko Iwano; Osamu Tohyama; Yoshihito Tsuji; Kazuhiko Nozaki; Nobuo Hashimoto; Toshihiko Fujimori; Yo-Ichi Nabeshima
Journal:  FEBS Lett       Date:  2004-05-07       Impact factor: 4.124

7.  Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX.

Authors:  Shiguang Liu; Rong Guo; Leigh G Simpson; Zhou-Sheng Xiao; Charles E Burnham; L Darryl Quarles
Journal:  J Biol Chem       Date:  2003-07-21       Impact factor: 5.157

8.  Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.

Authors:  Takashi Shimada; Makoto Kakitani; Yuji Yamazaki; Hisashi Hasegawa; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Kazuma Tomizuka; Takeyoshi Yamashita
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

Review 9.  FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.

Authors:  L Darryl Quarles
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-07       Impact factor: 4.310

10.  FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

Authors:  Mara Riminucci; Michael T Collins; Neal S Fedarko; Natasha Cherman; Alessandro Corsi; Kenneth E White; Steven Waguespack; Anurag Gupta; Tamara Hannon; Michael J Econs; Paolo Bianco; Pamela Gehron Robey
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

View more
  538 in total

1.  Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372.

Authors:  Mohammed S Razzaque
Journal:  Expert Opin Ther Pat       Date:  2010-07       Impact factor: 6.674

Review 2.  Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).

Authors:  Emily G Farrow; Erik A Imel; Kenneth E White
Journal:  Best Pract Res Clin Rheumatol       Date:  2011-10       Impact factor: 4.098

3.  Identification of novel small molecules that elevate Klotho expression.

Authors:  Gwendalyn D King; CiDi Chen; Mickey M Huang; Ella Zeldich; Patricia L Brazee; Eli R Schuman; Maxime Robin; Gregory D Cuny; Marcie A Glicksman; Carmela R Abraham
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

4.  Sustained Klotho delivery reduces serum phosphate in a model of diabetic nephropathy.

Authors:  Julia M Hum; Linda M O'Bryan; Arun K Tatiparthi; Erica L Clinkenbeard; Pu Ni; Martin S Cramer; Manoj Bhaskaran; Robert L Johnson; Jonathan M Wilson; Rosamund C Smith; Kenneth E White
Journal:  J Appl Physiol (1985)       Date:  2019-01-03

5.  Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.

Authors:  Andrew C Karaplis; Xiuying Bai; Jean-Pierre Falet; Carolyn M Macica
Journal:  Endocrinology       Date:  2012-10-04       Impact factor: 4.736

6.  FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action.

Authors:  Dong-Ju Shin; Timothy F Osborne
Journal:  J Biol Chem       Date:  2009-02-23       Impact factor: 5.157

Review 7.  Klotho and aging.

Authors:  Makoto Kuro-o
Journal:  Biochim Biophys Acta       Date:  2009-02-20

8.  Subtle Difference Generates Big Dissimilarity: Comparison of Enzymatic Activity in KL1 and KL2 Domains of Lancelet Klotho.

Authors:  Zengyu Ma; Baozhen Qu; Shenjie Zhong; Lan Yao; Zhan Gao; Shicui Zhang
Journal:  Mar Biotechnol (NY)       Date:  2019-05-03       Impact factor: 3.619

9.  A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.

Authors:  Shoji Ichikawa; Erik A Imel; Mary L Kreiter; Xijie Yu; Donald S Mackenzie; Andrea H Sorenson; Regina Goetz; Moosa Mohammadi; Kenneth E White; Michael J Econs
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

10.  The parathyroid is a target organ for FGF23 in rats.

Authors:  Iddo Z Ben-Dov; Hillel Galitzer; Vardit Lavi-Moshayoff; Regina Goetz; Makoto Kuro-o; Moosa Mohammadi; Roy Sirkis; Tally Naveh-Many; Justin Silver
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.